Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1353 - Measurement of Calprotectin as a marker of bowel inflammation

?

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat at msac.secretariat@health.gov.au

Comment on the Draft protocol closed at 1159 on 14 November 2014

Application Number1353
Application NameMeasurement of calprotectin as a marker of bowel inflammation
Description of Medical ServiceFaecal calprotectin is a marker for intestinal inflammation. Calprotectin concentration in faeces correlates with the severity of inflammation and is significantly increased in patients with bowel inflammation (IBD), but not elevated in patients with functional disorders like functional bowel disease (IBS). As a screening tool, faecal calprotectin tests reduce the need for invasive diagnostic procedures (such as colonoscopy), potentially leading to earlier diagnosis of IBD and IBS and subsequently improving patient management.
Description of Medical ConditionPatients present to a doctor with gastrointestinal symptoms suggestive of either organic (IBD) or functional (IBS) bowel disease, namely: chronic abdominal pain and discomfort; urgency and bloating; diarrhea; constipation; alternating bouts of diarrhea and constipation; and changes in bowel habits in the absence of alarm symptoms such as rectal bleeding or abnormal blood tests.
Consultation ProtocolUnratified Draft Protocol for Consultation (PDF 354 KB)
Unratified Draft Protocol for Consultation (Word 569 KB)

Feedback and Survey Form (PDF 44 KB)
Feedback and Survey Form (Word 71 KB)
Final Protocol-
Reports-
MSAC Outcomes-

Meetings for this Application

Meeting Type:Date:
PASC14 - 15 August 2014
ESC -
MSAC -

Page currency, Latest update: 18 November, 2014